AKBA stock news · Akebia Therapeutics, Inc.
Get alerts for AKBA
Follow Akebia Therapeutics, Inc. (AKBA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AKBAFree on the App Store and Google Play, or on the web.
Akebia Therapeutics has taken out a $140 million loan, starting with $60 million now.
Bad for AKBAAkebia borrowed $60 million, received $58.6 million after fees, and repaid its old $55 million loan. The costly secured debt and warrants make this unfavorable for the company.
Akebia Therapeutics says some directors and officers are leaving, and new ones are being chosen.
NeutralAkebia’s commercial chief plans to leave in November for personal reasons, then advise through April 2027. The filing reports no wider business change, so it does not shift the company’s outlook.